Fundraising FoxJDRF T1D Fund — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.
BiotechHealthtechMorrisville, US
Roger Jeffs(Co-Founder and Vice Chairman)inFraser Wright(Scientific Co-Founder and Chief Gene Therapy Officer)inShankar Ramaswamy(Founder)inMichele Stone(Chief Scientific Officer)inKatherine Eade(Chief Legal Officer)Britt Petty(Chief Manufacturing Officer)in
Co-investorsPatient Square CapitalPremji InvestAlumni VenturesAmplo VenturesAnjostBluebird Ventures+3 more
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)LAVLifeforce Capital+6 more
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Co-investorsAlumni VenturesHatteras Venture PartnersPappas CapitalSanofi VenturesAlexandriaGenesys Capital+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.